FDA grants Galenica/Luitpold OK to market anemia drug Injectafer
This article was originally published in Scrip
Executive Summary
Shares of Galenica jumped more than 8% on the Six Swiss Exchange on 26 July after the company and its partner Luitpold Pharmaceuticals gained approval from the FDA to market Injectafer (ferric carboxymaltose) as a treatment for iron deficiency anemia (IDA) in US adults who have had an unsatisfactory response to oral iron or who have intolerance to oral iron.